<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="637">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610554</url>
  </required_header>
  <id_info>
    <org_study_id>SARS-CoV-2_DLNO</org_study_id>
    <nct_id>NCT04610554</nct_id>
  </id_info>
  <brief_title>Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19</brief_title>
  <official_title>Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection with severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) may be associated with&#xD;
      diffuse alveolar damage and pulmonary vasculitis. Thus, it is likely that pulmonary function&#xD;
      changes may be seen in COVID-19 survivors. The aim of the present study was to test that&#xD;
      simultaneously-determined lung diffusing capacity for nitric oxide and carbon monoxide may be&#xD;
      useful to detect post-viral diffusive gas exchange abnormalities early after mild-to-severe&#xD;
      COVID-19-related pneumonias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infection with severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) may be asymptomatic or&#xD;
      associated with life-threatening interstitial pneumonia. Clinically, patients affected from&#xD;
      severe coronavirus disease-19 (COVID-19) are described as exhibiting rapidly progressing&#xD;
      acute respiratory failure with unusually low oxygen levels in arterial blood. On computed&#xD;
      tomography scans, diffuse, peripheral &quot;ground glass&quot; opacities of the lung are seen while&#xD;
      autopsy lung specimens showed diffuse alveolar damage and capillary endothelialitis.&#xD;
&#xD;
      The objective of the current study, conducted in patients who had recovered from&#xD;
      mild-to-severe COVID-19 illness, was to test that simultaneously-determined lung diffusing&#xD;
      capacity for nitric oxide (NO) and carbon monoxide (CO) may be of great use to early detect&#xD;
      post-infective diffusive gas exchange abnormalities. More specifically, we hypothesized that&#xD;
      measurement of membrane diffusive conductance for CO and pulmonary capillary volume may&#xD;
      provide accurate information on residual changes of peripheral gas exchanging units of the&#xD;
      lung related to previous SARS-CoV-2 infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2020</start_date>
  <completion_date type="Actual">October 12, 2020</completion_date>
  <primary_completion_date type="Actual">October 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung diffusing capacity for nitric oxide (DLNO)</measure>
    <time_frame>At a time interval ranging from 15 to 189 days after two nasopharyngeal swabs negative for SARS-CoV-2</time_frame>
    <description>Changes of DLNO after SARS-CoV-2 infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung diffusing capacity for carbon monoxide (DLco)</measure>
    <time_frame>At a time interval ranging from 15 to 189 days after two nasopharyngeal swabs negative for SARS-CoV-2</time_frame>
    <description>Changes of DLco after SARS-CoV-2 infection</description>
  </secondary_outcome>
  <enrollment type="Actual">74</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        We collected the data of 74 Caucasian consecutive subjects admitted to hospital who had&#xD;
        recovered from mild-to-severe COVID-19 and attended our laboratory as outpatients for&#xD;
        follow-up purposes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects were selected after two nasopharyngeal swabs negative for SARS-CoV-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe comorbidities potentially affecting pulmonary gas exchange&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Barisione, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sponsor should be IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Barisione G, Brusasco C, Garlaschi A, Baroffio M, Brusasco V. Lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias. J Appl Physiol (1985). 2016 May 1;120(9):1029-38. doi: 10.1152/japplphysiol.00964.2015. Epub 2016 Feb 18.</citation>
    <PMID>26893034</PMID>
  </reference>
  <reference>
    <citation>Barisione G, Bacigalupo A, Brusasco C, Scanarotti C, Penco S, Bassi AM, Lamparelli T, Garlaschi A, Pellegrino R, Brusasco V. Mechanisms for reduced pulmonary diffusing capacity in haematopoietic stem-cell transplantation recipients. Respir Physiol Neurobiol. 2014 Apr 1;194:54-61. doi: 10.1016/j.resp.2014.01.018. Epub 2014 Feb 1.</citation>
    <PMID>24495442</PMID>
  </reference>
  <results_reference>
    <citation>Barisione G, Garlaschi A, Occhipinti M, Baroffio M, Pistolesi M, Brusasco V. Value of lung diffusing capacity for nitric oxide in systemic sclerosis. Physiol Rep. 2019 Aug;7(13):e14149. doi: 10.14814/phy2.14149.</citation>
    <PMID>31264386</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>Giovanni Barisione</investigator_full_name>
    <investigator_title>MD - Chief, Respiratory Pathophysiology Unit</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

